Ticagrelor hits primary endpoint in the THALES Phase III trial for use in stroke

In this study, the manufacturers report that ticagrelor 90 mg twice daily plus aspirin for 30 days showed a statistically significant and clinically meaningful reduction in the risk of stroke and death vs aspirin alone.